Want your profile here?

Becoming a member is easy! works with you to help you advance your career by putting you directly in front of tens of thousands of recruiters in your field. Sign up today on

RssDrug Safety Specialist

To obtain a position in a clinical research setting with emphasis in drug safety and phamacovigilance where my medical and research background can be highly valuable.

Clinical Research

Medford, MA

About Me


Science & Biotech


Clinical Research


PUBLICATIONS 1. Breault DT, Min IM, Carlone DL, Farilla LG, Ambruzs DM, Henderson DE, Algra S, Montgomery RK, Wagers AJ, Hole N. Generation of mTert-GFP mice as a model to identify and study tissue progenitor cells. PNAS, 105(30):10420-10425, 2008. 2. Noushmehr H, D'Amico E, Farilla L, Hui H, Wawrowsky KA, Mlynarski W, Doria A, Abumrad NA, Perfetti R. Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. Diabetes, 54(2):472-81, 2005. 3. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab., 15(1):27-33, 2004. 4. Bulotta A, Farilla L, Hui H, Perfetti R. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys., 40(3 Suppl):65-78, 2004. 5. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology, 144(12):5149-58, 2003. 6. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Glucagon-like peptide-1 promotes islets cell growth and inhibits apoptosis in Zucker Diabetic Rats. Endocrinology, 143(11):4397-4408, 2002. 7. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of Glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. European Journal of Endocrinology, 146(6):863-9, 2002. 8. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, Dotta F, Di Mario U. Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512 BDC dominant autoantigen epitopes. European Journal of Immunology, 32(5):1420-7, 2002. 9. Pichurin P, Yan XM, Farilla L, Guo J, Chazenbalk GD, Rapoport B, McLachlan SM. Naked TSH receptor DNA vaccination: A TH1 T cell response in which interferon-gamma production, rather than antibody, dominates the immune response in mice. Endocrinology, 142(8):3530-3536, 2001. 10. Xiong Z, Farilla L, Guo J, McLachlan S, Rapoport B. Does the autoantibodies immunodominant region on thyroid peroxidase include amino acid residues 742-771? Thyroid, 11(3):227-23, 2001. 11. Farilla L, Dotta F, Di Mario U, Rapoport B, McLachlan SM. Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type 1. Autoimmunity, 32(3):161-166, 2000. 12. Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, Dotta F. Congenital autoimmune diabetes Mellitus. New Engl. J. Med, 342(20):1529-1531, 2000. 13. Mennuni C, Santini C, Lazzaro D, Dotta F, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. Identification of a novel type 1 diabetic-specific epitope by screening phage libraries with sera from pre-diabetic patients. J. Mol. Biol., 268(3): 599-606, 1997. 14. Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, Dotta F. Gangliosides in autoimmune diabetes. Diab. Met. Rev., 13(3):163-179, 1997. 15. Dotta F, Dionisi S, Farilla L, Di Mario U. The use of immunological markers in IDDM after more than 20 yeras from ICA description. Diabetes Metab. Rev. 12(2):121-6, 1996 16. Mennuni C, Santini C, Dotta F, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. J. Autoimmunity, 9(3):431-436, 1996. 17. Dotta F, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. Ganglioside antigens in autoimmune diabetes. Diab. Nutr. Metab., 9:215-220, 1996. 18. Dotta F, Dionisi S, Farilla L, Di Mario U. Prediction of Type 1 diabetes 20 years after the discovery of cytoplasmic ICA. Diab. Met. Rev. 12:121-126, 1996. 19. Dionisi S, Sentimentale A, Farilla L, Carabba B, Di Mario U, Dotta F. Gli autoanticorpi diretti contro il ganglioside pancreatico GM2-1 nel topo NOD appartengono alla sottoclasse IgG1. [Autoantibodies Against GM2-1 Ganglioside in NOD Mice Belong to the IgG-1 Subclass]. Atti del X Congresso Nazionale A.M.D.: 355-359, 1995. 20. Farilla L, Dionisi S, Carabba B, Previti M, Sentimentale A, Lenti L, Di Mario U, Dotta F. Ganglioside insulare GM2-1: identificazione di una nuova struttura glicolipidica coinvolta nell’autoimmunità beta cellulare. [Islet Ganglioside GM2-1 Identification of a New Glycolipid Molecule Involved in Beta-Cellular Autoimmunity]. Atti del X Congresso Nazionale A.M.D.: 351-354, 1995. 21. Sentimentale A, Tiberti C, Dionisi S, Farilla L, Torresi P, Andreani D, Di Mario U, Falorni A, Lernmark A, Dotta F. Il diabete di tipo 1 quale malattia autoimmuneneuroendocrina. [Type-1 Diabetes as a Neuroendocrine Autoimmune Disease]. Atti del X Congresso Nazionale A.M.D.: 345-349, 1995.

Ideal Companies:

Novartis, Merck, Pfizer, Biogen, Millenium pharmaceuticals, Vertex, Parexel, Wyeth, FDA

Education level:

Medical Degree

Will Relocate:



Medford, MA

Work Experiences

2/2007 - Present


Individual Contributor

  • Basic Research

12/2003 - 12/2004

Amgen Inc.

Individual Contributor

  • Basic Research

12/1998 - 10/2003

Cedars-Sinai Medical Center

Individual Contributor

  • Basic Research

11/1992 - 11/1998

"Umberto I" Hospital

Individual Contributor

  • Medical Doctor